Letters

As a disenfranchised victim of the peer-review system, I consider that the myriad proposals for modifying peer review are less than encouraging. In his letter “Can Peer Review Be Improved?” (May 4, 1987, P. 10), Moshe Wolman is more than correct when he points out the inhibitory effect peer review has on science. Innovative, creative ideas that depart from dogma are usually given unfundable priorities, especially when dealing with NIH. In 1985 NIH received more than 30,000 proposa

Written byRonald Paque
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

As a disenfranchised victim of the peer-review system, I consider that the myriad proposals for modifying peer review are less than encouraging. In his letter “Can Peer Review Be Improved?” (May 4, 1987, P. 10), Moshe Wolman is more than correct when he points out the inhibitory effect peer review has on science. Innovative, creative ideas that depart from dogma are usually given unfundable priorities, especially when dealing with NIH.

In 1985 NIH received more than 30,000 proposals and was able to fund only 19.6 percent of them. Looking at it another way, this figure tells us that only about 20 percent of our graduates are competent people. This terrible waste of human talent, money and national resources is a direct result of the inequitable, politically motivated, club-run peer-review system.

But scientists themselves are also to blame. Privately they complain a great deal about peer review, but never seem to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies